Reports

Sale

Non-Hodgkin’s Lymphoma Treatment Market

Global Non-Hodgkin’s Lymphoma Treatment Market Size, Growth: By Treatment Type: Immunotherapy, Targeted Therapy, Chemotherapy, Others; By Disease Type: B Cell Lymphoma, T Cell Lymphoma; By Diagnosis: Biopsy, Cell and Tissue Study, Blood Tests, Imaging Tests, Others; Regional Analysis; Supplier Landscape; 2024-2032

Global Non-Hodgkin’s Lymphoma Treatment Market Outlook

The global non-Hodgkin’s lymphoma treatment market attained a value of USD 13.44 billion in 2023. The market is expected to grow further at a CAGR of 7.2% during the forecast period of 2024-2032 to attain a value of USD 25.13 billion by 2032, driven by the rising technological advancement and the increased availability of treatments.

 

Non-Hodgkin’s Lymphoma Treatment Market: Introduction

Non-Hodgkin's lymphoma is the type of cancer that develops in the white blood cells of the immune system, which are also known as lymphocytes. When these white blood cells start growing abnormally, they start forming tumours throughout the body. 

 

Major sites of these lymph tissue include lymph nodes, spleen, bone marrow, thymus, digestive tract, adenoids, and tonsils, among others. NHL is inclusive of different types of blood cancers. The subtypes can either progress slowly (indolent subtype) or spread rapidly (aggressive subtype). The non-Hodgkin’s lymphoma can be of two types, that is B cells and T cells. B cells are the cells which are responsible for producing antibodies which help in fighting off infections. On the other hand, T cells have different functions, including the role of providing support to the B cells in antibodies production. 

 

While the exact cause of non-Hodgkin’s lymphoma continues to be ambiguous, some of the potential factors responsible for the condition are genetic factors, lifestyle, infections, weak immune system, occupation, and the medical history of the patient as well as their family, among other factors. 

 

The symptoms of the condition are sometimes so common that the patient tends to mistake them for general flu or virus. The signs and symptoms significantly rely on factors like the location of the tumour, its size, and its growth speed. The most common signs and symptoms of the disease include fever, nausea, fatigue, significant weight loss, skin problems like rashes or itchy skin, pain in bones, abdomen, or chest without any reason, severe sweat at night, and swollen lymph nodes, among others.

 

These symptoms can either happen separately or all at once. For instance, when symptoms like night sweats, severe weight loss, and fever happen together, then these symptoms are clubbed as B symptoms.

 

non-hodgkins lymphoma treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Non-Hodgkin’s Lymphoma Treatment Market Segmentations

The market can be categorized into segments like treatment type, disease type, diagnosis, and major regions.

 

Market Breakup by Treatment Type

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Others

 

Market Breakup by Disease Type

  • B Cell Lymphoma
  • T Cell Lymphoma

 

Market Breakup by Diagnosis

  • Biopsy
    • Bone Marrow Aspiration and Biopsy
    • Excisional or Incisional Biopsy
    • Needle Biopsy
  • Cell and Tissue Study
    • Fluorescence in situ Hybridization
    • Polymerase Chain reaction
    • Immunophenotyping
  • Blood Tests
    • Complete Blood Count
    • Blood Chemical Test
  • Imaging Tests
    • Chest X-Ray
    • CT Scan
    • MRI
    • Ultrasound
    • Bone Scan
    • PET Scan
  • Others

 

non-hodgkins lymphoma treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Non-Hodgkin's Lymphoma Treatment Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

Non-Hodgkin’s Lymphoma Treatment Market Scenario

The growth of the market is likely to grow significantly over the forecast period owing to the rising number of cases amongst children. The rising demand for the treatment market can also be attributed to the rising technological advancements, rising number of approved drugs and treatments, as well as the development of new and advanced drugs.

 

Globally, North America is anticipated to account for a significant share over the coming years since the region is technologically advances and the awareness about different types of cancer in the region is high. The awareness about the importance of conducting regular health check-ups has also propelled the growth of the market.  Other than North America, Europe and Asia Pacific are also likely to witness robust growth in the coming years with the rapidly rising number of cases across these regions.

 

non-hodgkins lymphoma treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Non-Hodgkin’s Lymphoma Treatment Market- Epidemiology

The prevalence of the disease is constantly across the globe. The total number of cases in the year 2023 reached around 570,000. Older people are more vulnerable to this condition, especially people belonging to the age group of 65-75; however, it can happen to anyone. Men are more likely to suffer from the disease than women. People who consume immunosuppressant drugs immediately after any organ transplant are also at a higher risk of having this condition.

 

NHL is a disease which attacks people who have a weaker immune system. Variety of factors could lead to a weaker immune system. These factors include inherited immunity ailments like Wiskott-Aldrich syndrome and hypogammaglobulinemia, autoimmune conditions like HIV/ AIDS, psoriasis, arthritis, or Sjögren syndrome, Helicobacter pylori infection, and Epstein-Barr virus infection or Human T-lymphotropic virus type I.

 

Non-Hodgkin’s Lymphoma Treatment Market- Therapeutic Landscape

Various treatment methods are used for NHL including radiation therapy, chemotherapy, immunotherapy, targeted therapy, Plasmapheresis, antibiotic therapy, and surgery, among others. The three major treatment methods covered in this report include the following:

 

Immunotherapy- This treatment uses the patient’s immunity system to fight the cancer cells. Medications are used to boost the immunity system of the patient to kill the cancer cells, which also helps in preventing further growth of cancer cells. Immunomodulators like Lenalidomide are used to treat adult non-Hodgkin lymphoma. Immunotherapy also includes the use of CAR T-cell therapy.

 

Targeted Therapy- This therapy uses certain drugs to attack the cancer cells. Some of the prominent therapies under this treatment type include proteasome inhibitor therapy, monoclonal antibody therapy, and kinase inhibitor therapy.

 

  • Proteasome Inhibitor Therapy: The inhibition of proteasome might help in killing the cancer cells. Drugs like Bortezomib or ixazomib are used in this treatment method.
  • Monoclonal Antibody Therapy: It comprises the use of drugs like Rituximab, Mogamulizumab, Brentuximab vedotin, Obinutuzumab, Tafasitamab, Polatuzumab vedotin, Pembrolizumab, and Yttrium Y 90-ibritumomab tiuxetan, among others.
  • Kinase Inhibitor Therapy: This therapy helps in inhibiting the growth of protein cells which might be contributing to the growth of cancer cells in the body. It includes the use of drugs like Copanlisib, acalabrutinib, zanubrutinib, and Ibrutinib.
  • Other treatments included in targeted therapy are Histone methyltransferase inhibitor therapy and B-cell lymphoma-2 (BCL-2) inhibitor therapy.

 

Chemotherapy- This treatment includes the use of drug which is given either orally or through drip or injections to the patient. In some cases, the patient might require a combination of both. To avoid the risk of cancer reaching the brain, these injections might be injected directly into the cerebrospinal fluid, that is around the spine. Chemotherapy is given in an interval of months, depending on the patient’s response to the drugs.

 

No matter which method of treatment is opted for the patient, these drugs are extremely strong and lead to sever side effects. Some of these toxic side effects also include loss of fertility, paralysis, different types of cancer, and baldness, among others.

 

Key Players in the Global Non-Hodgkin’s Lymphoma Treatment Market

The major companies working on the drugs and treatment of the condition, and investing in the clinical trials include the following:

 

  • Eli Lilly and Company
  • Corvus Pharmaceuticals
  • Rafael Pharmaceuticals
  • AbbVie
  • ADC Therapeutics
  • Genetech
  • Tessa Therapeutics
  • Bristol Myers Squibb

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment Type
  • Disease Type
  • Diagnosis
  • Region
Breakup by Treatment Type
  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Others
Breakup by Disease Type
  • B Cell Lymphoma
  • T Cell Lymphoma
Breakup by Diagnosis
  • Biopsy
  • Cell and Tissue Study
  • Blood Tests
  • Imaging Tests
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Eli Lilly and Company
  • Corvus Pharmaceuticals
  • Rafael Pharmaceuticals
  • AbbVie
  • ADC Therapeutics
  • Genetech
  • Tessa Therapeutics
  • Bristol Myers Squibb

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
2    Research Methodology
3    Executive Summary
4    Non-Hodgkin’s Lymphoma Overview

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1     Patient Profile Model
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate 
6    Current Scenario Evaluation and Regulatory Framework
    6.1    Emerging Therapies and Clinical Trials 
    6.2    Patent Landscape  
        6.2.1    Patent Overview 
            6.2.1.1    Patent Status and Expiry 
            6.2.1.2    Timelines from Drug Development to Commercial Launch 
            6.2.1.3    New Drug Application 
                6.2.1.3.1    Documentation and Approval Process 
        6.2.2    Cost of Treatment 
        6.2.3    Regulatory Framework 
            6.2.3.1    Regulatory Overview 
                6.2.3.1.1    US FDA 
                6.2.3.1.2    EU EMA 
                6.2.3.1.3    INDIA CDSCO 
                6.2.3.1.4    JAPAN PMDA 
                6.2.3.1.5    Others   
7    Challenges and Unmet Needs
    7.1    Treatment Pathway Challenges
    7.2    Compliance and Drop- out Analysis
    7.3    Awareness and Prevention Gaps
8    Global Non-Hodgkin’s Lymphoma Treatment Market
    8.1    Global Non-Hodgkin’s Lymphoma Treatment Market Overview
    8.2    Global Non-Hodgkin’s Lymphoma Treatment Market Analysis 
        8.2.1     Market Overview
            8.2.1.1    Global Historical Non-Hodgkin’s Lymphoma Market Value (2017-2023) 
            8.2.1.2    Global Forecast Non-Hodgkin’s Lymphoma Market Value (2024-2032)
    8.3    Global Non-Hodgkin’s Lymphoma Treatment Market by Treatment Type
        8.3.1     Market Overview
            8.3.1.1    Immunotherapy
            8.3.1.2    Targeted Therapy
            8.3.1.3    Chemotherapy
            8.3.1.4    Others
    8.4    Global Non-Hodgkin’s Lymphoma Treatment Market by Disease Type
        8.4.1     Market Overview
            8.4.1.1    B Cell Lymphoma
            8.4.1.2    T Cell Lymphoma
    8.5.    Global Non-Hodgkin’s Lymphoma Treatment Market by Diagnosis
        8.5.1     Market Overview
            8.5.1.1    Biopsy
                8.5.1.1.1    Bone Marrow Aspiration and Biopsy
                8.5.1.1.2    Excisional or Incisional Biopsy
                8.5.1.1.3    Needle Biopsy
            8.5.1.2    Cell and Tissue Study
                8.5.1.2.1    Fluorescence in situ Hybridization
                8.5.1.2.2    Polymerase Chain reaction
                8.5.1.2.3    Immunophenotyping
            8.5.1.3    Blood Tests
                8.5.1.3.1    Complete Blood Count
                8.5.1.3.2    Blood Chemical Test
            8.5.1.4    Imaging Tests
                8.5.1.4.1    Chest X-Ray
                8.5.1.4.2    CT Scan
                8.5.1.4.3    MRI
                8.5.1.4.4    Ultrasound
                8.5.1.4.5    Bone Scan
                8.5.1.4.6    PET Scan
            8.5.1.5    Others
    8.6    Global Non-Hodgkin’s Lymphoma Treatment Market by Region 
        8.6.1    Market Overview 
            8.6.1.1    North America  
            8.6.1.2    Europe 
            8.6.1.3    Asia Pacific 
            8.6.1.4    Latin America 
            8.6.1.5    Middle East and Africa 
9    North America Non-Hodgkin’s Lymphoma Treatment Market
    9.1    United States of America 
        9.1.1    Historical Trend (2017-2023) 
        9.1.2    Forecast Trend (2024-2032) 
    9.2    Canada  
        9.2.1    Historical Trend (2017-2023) 
        9.2.2    Forecast Trend (2024-2032) 
10    Europe Non-Hodgkin’s Lymphoma Treatment Market
    10.1    United Kingdom 
        10.1.1    Historical Trend (2017-2023) 
        10.1.2    Forecast Trend (2024-2032) 
    10.2    Germany 
        10.2.1    Historical Trend (2017-2023) 
        10.2.2    Forecast Trend (2024-2032) 
    10.3    France 
        10.3.1    Historical Trend (2017-2023) 
        10.3.2    Forecast Trend (2024-2032) 
    10.4    Italy 
        10.4.1    Historical Trend (2017-2023) 
        10.4.2    Forecast Trend (2024-2032) 
11    Asia Pacific Non-Hodgkin’s Lymphoma Treatment Market
    11.1    China 
        11.1.1    Historical Trend (2017-2023) 
        11.1.2    Forecast Trend (2024-2032) 
    11.2    Japan 
        11.2.1    Historical Trend (2017-2023) 
        11.2.2    Forecast Trend (2024-2032) 
    11.3    India 
        11.3.1    Historical Trend (2017-2023) 
        11.3.2    Forecast Trend (2024-2032) 
    11.4    ASEAN 
        11.4.1    Historical Trend (2017-2023) 
        11.4.2    Forecast Trend (2024-2032) 
    11.5    Australia 
        11.5.1    Historical Trend (2017-2023) 
        11.5.2    Forecast Trend (2024-2032) 
12    Latin America Non-Hodgkin’s Lymphoma Treatment Market
    12.1    Brazil 
        12.1.1    Historical Trend (2017-2023) 
        12.1.2    Forecast Trend (2024-2032) 
    12.2    Argentina 
        12.2.1    Historical Trend (2017-2023) 
        12.2.2    Forecast Trend (2024-2032) 
    12.3    Mexico 
        12.3.1    Historical Trend (2017-2023) 
        12.3.2    Forecast Trend (2024-2032) 
13    Middle East and Africa Non-Hodgkin’s Lymphoma Treatment Market
    13.1    Saudi Arabia 
        13.1.1    Historical Trend (2017-2023) 
        13.1.2    Forecast Trend (2024-2032) 
    13.2    United Arab Emirates 
        13.2.1    Historical Trend (2017-2023) 
        13.2.2    Forecast Trend (2024-2032) 
    13.3    Nigeria 
        13.3.1    Historical Trend (2017-2023) 
        13.3.2    Forecast Trend (2024-2032) 
    13.4    South Africa 
        13.4.1    Historical Trend (2017-2023) 
        13.4.2    Forecast Trend (2024-2032)
14    Global Non-Hodgkin’s Lymphoma Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces Model
    14.4    Key Demand Indicators
    14.5    Key Price Indicators
    14.6    Industry Events, Initiatives, and Trends 
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Eli Lilly and Company
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2     Corvus Pharmaceuticals
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Rafael Pharmaceuticals
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    AbbVie
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5     ADC Therapeutics
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6     Genetech
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7     Tessa Therapeutics
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8     Bristol Myers Squibb
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
16    Non-Hodgkin’s Lymphoma Treatment Market- Drug Distribution Model (Additional Insight)
    16.1    Overview 
    16.2    Potential Distributors 
    16.3    Key Parameters for Distribution Partner Assessment 
17    Payment Methods (Additional Insight)
    17.1    Government Funded
    17.2    Private Insurance
    17.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the market attained a value of nearly USD 13.44 billion.

The market is projected to grow at a CAGR of 7.2% during the forecast period of 2024-2032.

The market is estimated to witness robust growth during the forecast period of 2024-2032 to reach a value of USD 25.13 billion by 2032.

The growth of the market is driven by the rising prevalence of the disease, availability of treatment, and the technological advancement in the healthcare sector.

The rising awareness about the importance of early detection acts as a key trend for the market.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The treatment types include immunotherapy, targeted therapy, and chemotherapy, among others.

The disease can be divided into two types, B-cell and T-cell lymphoma.

The diagnosis methods include Biopsy, Cell and Tissue Study, Blood Tests, and imaging types, among others.

The major players in the market are Eli Lilly and Company, Corvus Pharmaceuticals, Rafael Pharmaceuticals, AbbVie, ADC Therapeutics, Genetech, Tessa Therapeutics, and Bristol Myers Squibb.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER